anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients receive 1000 mg/m\^2 gemcitabine hydrochloride IV on days 1, 8, and 15; and 100 mg oral erlotinib hydrochloride on days 1-28. Treatment repeats every 28 days for 2 courses. Patients achieving a complete response (CR) after 2 courses receive 2 additional courses of treatment; patients achieving a partial response (PR) receive retreatment as above. Patients achieving a CR after 4 courses of treatment receive erlotinib hydrochloride until the first disease progression. After the first progression, patients are retreated with gemcitabine hydrochloride and erlotinib hydrochloride until second progression.
The invention provides an anti-human RANKL antibody, a humanized antibody thereof, a pharmaceutical composition thereof and application thereof, wherein the anti-human RANKL antibody can be specifically combined with the amino acid sequence shown in SEQ ID NO. 1, the heavy chain of the anti-human RANKL antibody comprises a variable region shown in one of the amino acid sequences of SEQ ID NO. 2-9, and the light chain of the anti-human RANKL antibody comprises a variable region shown in one of the amino acid sequences of SEQ ID NO. 10-17. The humanized antibody can specifically bind to human RANKL, and the heavy chain variable region of the humanized antibody is selected from the amino acid sequences shown in SEQ ID NO. 6, 23, 25, 27 or 29, and the light chain variable region of the humanized antibody is selected from the amino acid sequences shown in SEQ ID NO. 14, 31, 33, 35, 37 or 39.
The invention discloses a traditional Chinese medicine preparation for treating cough caused by intrinsic heat in lung and lung-heat cough type chronic bronchitis, which is characterized by being prepared from the following raw materials in parts by weight: 30-50 parts of Japanese ardisia, 15-35 parts of roughhaired holly, 5-25 parts of wild chrysanthemum flower, 5-25 parts of loquat leaf and 1-15 parts of liquorice. The traditional Chinese medicine composition has the effects of clearing heat, promoting fluid production, clearing lung heat, relieving cough and clearing lung qi, can clear heat in lung, can clear lung qi and relieve cough by combining the whole formula, and can achieve the curative effect of treating chronic bronchitis. The effective rate of the traditional Chinese medicine for treating simple cough or chronic cough caused by lung heat syndrome differentiation in lung reaches 100%. In the non-attack stage, lung, spleen and kidney qi are deficiency-type, and are easy to repeatedly infect and cough and asthma are incessant. The invention can tonify lung qi and enhance immunity; invigorating spleen qi, eliminating phlegm, and relieving cough; when kidney qi is warmed, dyspnea and cough can be relieved by  due to the abundance of kidney qi. The prescription of the invention is compatible with dispersing and eliminating phlegm, and can achieve the purpose of relieving cough and asthma.
This study will focus on athletes who are at a higher risk of lower extremity stress fractures. Specifically, this study will be looking at male and female athletes on the track, cross-country, soccer, and basketball teams at the University of South Carolina. During the pre-season physical of each student athlete, serum vitamin D levels will be taken and recorded. There will be a certified nurse to draw the blood samples. This will take place at the University of South Carolina Athletic Department and/or the Palmetto Health Lab at 2 Medical Park. Potentially, every athlete of the given teams will be enrolled in the study unless they choose not to. Only subjects showing concentrations below 30 ng/mL, which is indicative of insufficient or deficient levels, will be provided supplemental treatment of 25-(OH) vitamin D. Every enrolled subject will be monitored for injury throughout the season. Any and all injuries will be positively identified, and any confirmed stress fractures will be recorded. Data from prospective seasons will be compared to an incidence percentage of athletes from previous seasons. Previous athletes did not receive any vitamin D treatment. These will be used as a control to determine if treatment affected the occurrence of stress fractures. All physicals and tests will be performed at the University of South Carolina Sports Medicine clinic by the sports medicine staff.
PURPOSE: To obtain a highly safe biological hyarulonic acid synthesis promoter capable of activating cutaneous cells and preventing the skin from aging owing to having excellent biological hyarulonic acid synthesis promotive effect, containing, as active ingredient, an extract of the sea algae belonging to Gloiopeltis. CONSTITUTION: This promoter contains, as active ingredient, an extract of the sea algae belonging to Gloiopeltis (e.g. Gloiopeltis furcata J. Agardh, Gloiopeltis tenax J. Agardh). The extract is pref. obtained by subjecting the above sea algae to extraction with a water/lower alcohol mixed solvent with the volume ratio of (100:0) to (30:70) at 5-80 deg.C for 1-24h under agitation so as to make the weight ratio of the original sea algae (on a dry basis) to the solvent (1:50) to (1:2). When the promoter is to be used as a skin preparation for external use, it is preferable that 0.1-10wt.% of the above extract be formulated in the skin preparation.
BACKGROUND: Despite significant progress in orthopaedic surgery, the prevalence of periprosthetic joint infections (PJIs) remains persistent, and future increases are expected due to the increasing number of joint arthroplasties. PJIs are intricately connected to biofilm-producing bacteria, which encase infected prostheses, impairing the effectiveness of antibiotics and the immune system. Acute PJIs with immature biofilms are traditionally managed with debridement, antibiotics, and implant retention (DAIR). However, to date, there has not been a conclusive direct clinical comparison (in vivo) demonstrating the superiority of one irrigation solution over others. Recently, there has been a growing interest in irrigation solutions with antibiofilm properties demonstrated in in vitro studies, exemplified by the preformulated Bactisure® irrigation solution, which contains ethanol, acetic acid, sodium acetate, benzalkonium chloride, and sterile water. The main objective of this study was to evaluate the effectiveness (infection cure rate) of preformulated Bactisure® irrigation solution in vivo compared with saline solution in a control group of patients with acute knee and/or hip periprosthetic infections treated with DAIR.
METHODS: Prospective single-centre randomized controlled trial involving patients with acute haematogenous PJI who received standard DAIR surgery from December 2022 to December 2024. The type of irrigation solution used during surgery will include two groups allocated at a 1:1 ratio: a control group (n = 25) with saline solution and an experimental group (n = 25) receiving the Bactisure® preformulated solution. The sample size was calculated based on an expected reduction in reinfection rates from 45% in the control group to 10% in the experimental group. Data on baseline patient characteristics, clinical and radiological information, and healthcare questionnaires will be recorded. All patients will be followed for minimum of 12 months. The infection cure rate at 1 year will be the primary outcome.
DISCUSSION: This study is the first to compare the effectiveness of preformulated Bactisure® irrigation solution with that of saline solution in real clinical practice (in vivo) in patients with acute knee and/or hip periprosthetic infections treated with DAIR. Our main hypothesis is that, compared with saline solution, Bactisure® provides a better infection cure rate at 1 year post-DAIR.
TRIAL REGISTRATION: International Standard Randomized Controlled Trial Number (ISRCTN): https://doi.org/10.1186/ISRCTN10873696 . Registered on December 19, 2023.
FIELD: technology of processing of raw materials of natural origin, particularly, antlers of Siberian stags, Manchurian deers, dapple and northern deers for producing biologically active powder from antlers applicable in food, medical and biotechnological industries. SUBSTANCE: method includes mechanical removal of hair side from antlers of Siberian stag, Manchurian or dapple deers, crushing of material to obtain particles sizing 5-10 mm and its drying with air flow at temperature of not in excess of 70 C, repeated crushing of material to average size of particles of 0.1 mm and replaced drying in air flow at the same temperature. Introduced into obtained product is ferromagnetic powder with particles sizing 1.0-50.0 mcm in ratio from 1:1 to 2:1. Product is subjected to additional reduction in size in vortex mill in presence of the ferromagnetic powder to obtain ultradispersed material from antlers with particles sizing 0.1-30 mcm and moisture content of not in excess of 2 wt.%. Ferromagnetic powder is removed from mixture by means of permanent magnetic field. Ready powdery product is packed in vacuum packages. EFFECT: preparation of biologically active powder product from antlers featuring high bioaccessibility and assimilation by organism. 3 cl, 1 tbl, 5 ex
BACKGROUND: Mesenchymal stem cells (MSC) is a promising alternative method in liver cirrhosis management. Several administration routes of MSC have been studied, but few studies compared one to another. The purpose of this study is to compare the intrahepatic and intrasplenic route of MSC administration in terms of liver function and degree of liver fibrosis in the bile duct ligation model in rabbits.
METHOD: Experimental study was conducted using rabbits (Oryctolagus cuniculus) model undergoing bile duct ligation (BDL). The subjects were randomized into 4 groups: sham surgery; bile duct ligation; bile duct ligation followed by intrahepatic route of MSC (BDL + IH MSC), and bile duct ligation followed by intrasplenic route of MSC (BDL + IS MSC). Umbilical cord mesenchymal stem cell (UC MSC) was administered on the fifth day after bile duct ligation, and the subjects were observed until the fourteenth day after bile duct ligation. The liver function was evaluated with alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total and direct bilirubin. The degree of fibrosis was evaluated with Laennec score, fibrosis area fraction, the number of viable and necrosis hepatocytes, and the number of hepatic progenitor cells.
RESULT: The subjects were randomized into 4 groups: 2 in sham surgery group, and 7 in each of the following groups: BDL, BDL + IH MSC and BDL + IS MSC groups. The mortality rate in BDL group was 57.1 %, while mortality in BDL + IH MSC and BDL + IS MSC groups were 14.3 % and 28.6 % respectively. No significant difference was found regarding liver function in each group, such as AST, ALT, total, and direct bilirubin. Histopathology examination in almost every subject undergone bile duct ligation (regardless of MSC administration) showed degree of fibrosis of Laennec 4B. Fibrosis area fraction, the number of viable and necrotic hepatocytes, and progenitor cells were analyzed; no significant difference was found between BDL + IH MSC and BDL + IS MSC groups, but the groups administered with MSC showed a larger number of viable hepatocytes compared to BDL group. No difference was found between BDL + IH MSC and BDL + IS MSC groups in terms of liver function and histologic parameters.
CONCLUSION: Administration of MSC increases the number of viable hepatocytes, but no difference was found in terms of liver function and degree of liver fibrosis between the intrahepatic route and intrasplenic route of administration.
TYPE OF STUDY: Animal Research, Randomized Controlled Study.
LEVEL OF EVIDENCE: Level I? (animal research is not indicated in the levels of evidence table in the journal website).
Once weekly (every 7 days) s.c. administration of 0.35 mL placebo If PASI50 is not reached after 8 weeks (week 8), the dosing will be increased to 0.45 mL placebo/week. Primary endpoint after 16 weeks. After 16 weeks patients will receive 17.5 mg MTX / week. If PASI50 is not reached after 8 weeks of MTX treatment (week 24), uptitration to 22.5 mg MTX/ 0.45 mL Plac / week will be done. Patients, who will reach PASI75 under placebo treatment after 16 weeks, will be dosed neither with placebo nor with MTX until relapse. After relapse the patients will be dosed with a starting dose of 17.5 mg MTX / week.
This study is an unblinded randomized controlled clinical trial. The study will be conducted on people with mild to moderate hypertriglyceridemia whose fasting blood triglyceride levels were between 150-499 mg/dL in the previous two tests. Participants who meet the following criteria will not be included in the study: Being treated with fibrate medications, end-stage kidney disease, acquired immunodeficiency syndrome patients, cancer patients undergoing chemotherapy or radiotherapy, patients with liver cirrhosis, being treated glucocorticoids, continuous use of omega-3 supplements or in the past month, and pregnancy or lactation.

Patients will be randomly assigned to one of three study groups. The duration of the study will be 8 week. The groups are: the control group, which is given a placebo pearls containing sunflower oil. the omega-3 oil group will be given omega-3 pearls, and the chia seed group that will consume chia seeds. In addition, the participants of all three groups are subjected to a low-calorie diet. At the beginning and end of the study, the measurements include body weight, blood pressure, blood concentration of lipids, lipoproteins and inflammatory factors.
The embodiments of the present invention relate to a medical information search apparatus. The present invention provides a medical information search apparatus which can support a user in retrieving a desired electronic medical record even if the text information registered in the electronic medical record varies in expression or the text information is not registered in the electronic medical record. According to one embodiment, a medical information search apparatus includes a registration unit, a search condition acquisition unit, and a search unit. The registration unit is configured to register, in a management server, at least medical information and information of a schema template included in the medical information associated with each other. The search condition acquisition unit is configured to acquire information of the schema template based on a search condition set by a user through an input unit. The search unit is configured to retrieve, from the management server, medical information associated with information of the schema template acquired by the search condition acquisition unit.
PROBLEM TO BE SOLVED: To obtain a stable powder composition which suffers no effusion of oily components and is excellent in solubility in water and free from a protein by employing a specific amount, relative to the oily components, of gum arabic and saccharides. SOLUTION: The wt. ratio of an oily component to gum arabic is 2:1 to 1:5 and the wt. ratio of the gum arabic to saccharides is 5:1 to 1:100. The saccharides are preferably at least one selected from monosaccharides, disaccharides and derivatives thereof, that is, sugar alcohols. A powdery oil and fat composition is preferably prepared by gradually adding the oily component to the gum arabic and saccharides previously dissolved in water and homogenizing after preemulsification thereby emulsifying. As a homogenizing machine can be used a homogenizer, a homomixer and the like. Powdering of the emulsion is suitably carried out by spray drying. As the oily components can be exemplified vegetable and animal oils and fats, oil-soluble vitamins, oil-soluble perfumes, sterols, oil-soluble emulsifier and the like.
Specially designed non-mammalian GnRH, its analogs, or biometics resistant to degradation by peptidase, are disclosed. The GnRH analogs are further defined as analogs of GnRH II or salmon GnRH. These non-mammalian analogs incorporate D-arginine, D-leucine, D-tBu-Serine, D-Trp or other active D amino acids at position 6 and ethylamide, aza-Gly-amide or other Gly amide at position 10. The D-Arg (6) - GnRH II - ethylamide, D-Arg (6) - GnRH II-aza-Gly (10)-amide, the D-Arg (6) - salmon GnRH ethylamide, and D-Arg (6) - salmon GnRH-aza-Gly (10)-amide analogs are also provided, and demonstrate preferential binding to immune system non-mammalian GnRH receptors. These non-mammalian GnRH or its analogs, or long-acting preparation, biometics or their antibodies may be used in pharmaceutical preparation, and specifically in treatment of various immune system disorders. The non-mammalian GnRH or its analogs are also provided in pharmaceutical preparations that may be used clinically for treating immune system disorders when used in very low doses and administered in pulsatile fashion. The aza-Gly (10) amide non-mammalian analogs are yet other embodiments of the non-mammalian GnRH or its analogs provided as a part of the invention. The use of agents that regulate the production or antibodies or In addition, the detection of non-mammalian GnRH or GnRH II or the non-mammalian GnRH receptors may be used as a diagnostic tool.
PURPOSE:To obtain an antimicrobial film having an excellent gradual releasing property of antimicrobial agents, giving an even antimicrobial action and suitably used as a food products-packing film in particular. CONSTITUTION:One side surface of a base film of PET 1 is coated with a hot-melt EVA adhesive power to which AITC cyclodextrin clathrate 2 is added to form the adhesive layer 3. The amount of the powder is 10 pts.wt. per 100 pts.wt. of the hot-melt adhesive. After a sealant film of PET 4 is adhered through the adhesive layer 3 to the base film 1 by hot melting, only the sealant film is bored by irradiation with laser beams to form a number of through-holes 5 of 5mum diameter in the thickness direction to give the objective antimicrobial film 11.
The overarching goal of this study is to improve mobility in older adults through advances in wearable assistance (i.e. powered orthoses). This goal will be accomplished by focusing on two specific research aims. The first aim is to study if targeted ankle resistance gait training improves walking performance in older individuals. The second aim is to evaluate the potential of wearable assistance at the ankle, knee, and/or hip joints to increase walking performance in older individuals.

Several powered orthosis conditions will be tested during several modes of walking or running and balance throughout the course of the study. Trials will take place over-ground and/or on a treadmill. Balance trials will take place on a treadmill. Participants will walk for up to 40 minutes. Frequent breaks will be provided between trials and conditions to avoid fatigue; a maximum of 15 minutes of continuous walking will take place between breaks.
Patients receive olaparib PO BID, and tremelimumab IV over 1 hour and durvalumab IV over 1 hour on day 1. Treatment with olaparib continues for up to 12 months in the absence of disease progression or unacceptable toxicity. Treatment with tremelimumab repeats every 4 weeks for up to 4 courses and treatment with durvalumab repeats every 4 weeks for up to 13 courses in the absence of disease progression or unacceptable toxicity.
Approximately 25 subjects will receive a standard WHO adult potency BCG immunization (1cc/50mg live mycobacilli) in the deltoid. Following a wait period after BCG vaccination, patients will then receive standard strength BCG intravesical therapy once a week for a total of 6 weeks. The BCG is instilled and held in the bladder for approximately 2 hours. While the BCG is retained in the bladder the patient should be repositioned every 30 minutes to maximize bladder surface exposure to the agent. Patients will undergo a cystoscopy every 3 months following most recent TURBT. Study duration last approximately 6 months.
PURPOSE: The intraoperative detection of cerebrospinal fluid (CSF) leaks during endoscopic skull base surgery is critical to ensure watertight sealed defects. Intrathecal fluorescein (ITF) is a valuable adjunct to intraoperative investigation. Hence, our aim is to summarize the evidence of the efficacy of ITF as an accurate diagnostic modality and reconstruction guide for non-congenital skull base defects.
METHODS: Using the Cochrane Central, MEDLINE, and Embase databases, we identified studies involving the use of ITF in non-congenital CSF leaks which were published until November 2023. The STATA 18 software was used for meta-analysis.
RESULTS: Fourteen studies met the inclusion criteria, in which seven studies were included in the meta-analysis. ITF was used in 1898 (90.3%) of patients, with a detection rate of 88.1%. The overall detection rate of non-congenital CSF leaks among ITF concentrations of 5% and 10% had a statistically significant pooled effect size of 2.6 (95% CI = 2.25, 2.95), while when comparing the ITF to other alternative radiological tests, it was not statistically significant with a mean difference of 0.88 (95% CI = - 0.4, 2.16). Moreover, the pooled prevalence was statistically significant in regards of the complications associated with ITF with an effect size of 0.6 (95% CI = 0.39, 0.82), indicating that 60% of patients who underwent ITF would experience at least one of the measured complications.
CONCLUSION: ITF is considered as an efficient tool in localizing skull base defects. However, there was no significant results when comparing the ITF to other alternative radiological tests. Accordingly, if the ITF intervention is indicated, patients should be carefully selected based on their clinical need.
The lack of a certificate program specific to pediatric diabetes nursing of the Ministry of Health in our country and the insufficient number of diabetes education nurses show that the pediatric population is not adequately trained to provide diabetes management. Along with these obstacles, the lack of use of an evidence-based standard education program reveals the need for effective intervention programs that include approaches specific to adolescents, who are a particularly risky group. Peer interaction can be used as an effective approach to increase adolescents' adherence to treatment. Thus, adolescents who isolate themselves are given the opportunity to cope with the disease and to share with other children. It has been determined that there is no study in the literature that includes peer-interactive group support on adolescents with a diagnosis of Type 1 diabetes who have poor glycemic control but have repeated hospitalizations. This situation shows that there is a need for a study to evaluate the effect of educational intervention including peer-interactive group support on repeated hospitalizations in adolescents with Type 1 diabetes.
Active Comparator: Combination of Methotrexate (up to 25 mg per week), Leflunomide (20 mg once a day) and Hydroxychloroquine (200-400 mg once at night). All drugs are to be taken orally. Duration of therapy is for 3 months. All patients will receive folic acid (5 mg twice a week) along with methotrexate. Low dose prednisolone (weeks 1-2: 7.5 mg/day, weeks 2-4: 5 mg/day, weeks 4-6: 5 mg on alternate day and then stop) will be given as bridging therapy.